Call for Projects: P01 for Brain Tumors (Jan. 2022)
Duke Neurosurgery and The Preston Robert Tisch Brain Tumor Center are interested in your participation in a clinical Program Project Grant (PPG) for brain tumors. They have an existing P01 grant that they are looking to renew in the near future and would like to engage a diverse group of disciplines in this endeavor.
The team leading this grant application effort is part of a program that has held an active NIH P01 or P50 (SPORE) grant for more than 35 years and is currently ranked #4 in total NIH funding awarded.
Principal Investigators include John Sampson, MD, PhD, MHSc, MBA, and David Ashley, MBBS, FRACP, PhD, who have held PPG or R01 level funding for more than 25 years. Dr. Sampson is PI on the current Duke P01 “Experimental Therapy for Brain Tumors” and co-PI with Francis Ali-Osman, MD, DSc, on the “Duke SPORE in Brain Cancer.”
John H. Sampson, MD, PhD, MHSc, MBA, is the Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery; Professor of Pathology, Immunology, and Radiation Oncology; and Director of the Duke Brain Tumor Immunotherapy Program. He is also the immediate past Chair of the Department of Neurosurgery and current president of the Private Diagnostic Clinic (PDC), the physician practice of Duke Health. Dr. Sampson is recognized internationally as a leader in the surgical and experimental treatment of brain tumors with a focus on immunotherapy and drug delivery to the brain. He has served as PI on multiple early phase biologic clinical protocols and sponsor on multiple FDA IND applications and has served as PI for a number of worldwide Phase 3 registration trials. Dr. Sampson is the top ranked NIH funded researcher in neurosurgery.
David M. Ashley, MBBS, FRACP, PhD, is the Rory David Deutsch Distinguished Professor of Neuro-Oncology; Professor of Neurosurgery, Medicine, Pediatrics, and Pathology; Director of Duke’s Preston Robert Tisch Brain Tumor Center (PRTBTC); and Co-Leader of the Duke Comprehensive Cancer Centers’ Neuro-Oncology program. He is credentialed in both pediatric and adult neuro-oncology practice and is internationally considered a top figure in pediatric brain tumor research. His primary focus has been on neurologic tumors and the development of innovative therapies and approaches to care. He has been the principal investigator of a number of important national and international studies, both clinical and pre-clinical, and has had continuous national peer-reviewed grant funding at the NH&MRC (Australia) and the NIH (U.S.) at the very highest levels, including project and program level, since 1993.
Submit Your Work
If you have an interest in participating in the P01 application, please submit a simple, 3-5 sentence summary of what your project might entail using this link (https://duke.qualtrics.com/jfe/form/SV_5igtvwdOf8fTCL3), and the team will follow up to learn more about your work.
They are looking at a P01 submission date of January 2022. If you have any questions, please email Tecca Wright.